|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | A position statement on NAFLD/NASH based on the EASL 2009 special conference显示文摘 | Vlad Ratziu Stefano Bellentani Helena Cortez-Pinto Chris Day Giulio Marchesini | 2010 | Journal of Hepatology2010，，2： | 9 |
| 2 | Review article: the diagnosis of non‐alcoholic fatty liver disease – availability and accuracy of non‐invasive methods显示文摘 | D. Festi R. Schiumerini L. Marzi A. R. Di Biase D. Mandolesi L. Montrone E. Scaioli G. Bonato G. Marchesini‐Reggiani A. Colecchia | 2012 | Aliment Pharmacol Ther2012，，4： | 6 |
| 3 | Stage of change and motivation to healthier lifestyle in non-alcoholic fatty liver disease显示文摘 | Elena Centis Simona Moscatiello Elisabetta Bugianesi Stefano Bellentani Anna Ludovica Fracanzani Simona Calugi Salvo Petta Riccardo Dalle Grave Giulio Marchesini | 2012 | Journal of Hepatology2012，，： | 5 |
| 4 | Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome显示文摘 | Giulio Marchesini Elisabetta Bugianesi Gabriele Forlani Fernanda Cerrelli Marco Lenzi Rita Manini Stefania Natale Ester Vanni Nicola Villanova Nazario Melchionda Mario Rizzetto | 2003 | Hepatology2003，，4： | 5 |
| 5 | HFE Genotype, Parenchymal Iron Accumulation, and Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease显示文摘 | Luca Valenti Anna Ludovica Fracanzani Elisabetta Bugianesi Paola Dongiovanni Enrico Galmozzi Ester Vanni Elena Canavesi Ezio Lattuada Giancarlo Roviaro Giulio Marchesini Silvia Fargion | 2010 | Gastroenterology2010，，3： | 4 |
| 6 | Expanding the natural history of nonalcoholic steatohepatitis: From cryptogenic cirrhosis to hepatocellular carcinoma显示文摘 | Elisabetta Bugianesi Nicola Leone Ester Vanni Giulio Marchesini Franco Brunello Patrizia Carucci Alessandro Musso Paolo De Paolis Lorenzo Capussotti Mauro Salizzoni Mario Rizzetto | 2002 | Gastroenterology2002，，1： | 4 |
| 7 | Physical activity support or weight loss counseling for nonalcoholic fatty liver disease?显示文摘AIM:To determine the clinical effectiveness of intense psychological support to physical activity(PA)in nonalcoholic fatty liver disease(NAFLD),compared with cognitive-behavioral treatment(CBT).METHODS:Twenty-two NAFLD cases received support to exercise,tailored to their motivational needs(PA group).The effects on body weight,physical fitness[6-min walk test,VO2max and the PA-rating(PA-R)questionnaire]and body fat(fatty liver indices and visceral adiposity index)were compared with data obtained in 44 NAFLD subjects enrolled in a CBT program for weight loss,after adjustment for propensity score,calculated on baseline data.Measurements were performed at baseline,at 4-mo and one-year follow-up.Changes in anthropometric,biochemical and PA parameters were tested by repeated measurement ANOVA.Outcome results were tested by logistic regression analysis.RESULTS:At the end of the intensive program,BMI was less significantly reduced in the PA group(-1.09±1.68 kg/m2 vs-2.04±1.42 kg/m2 in the CBT group,P=0.019)and the difference was maintained at 1-year follow-up(-0.73±1.63 vs-1.95±1.88,P=0.012)(ANOVA,P=0.005).PA-R was similar at baseline,when only 14%of cases in PA and 36%in CBT(P=0.120)recorded values≥3.At 4 mo,a PA-R≥3 was registered in 91%of PA and 46%of CBT,respectively(P<0.001)and PA-R≥5(up to 3 h/wk of moderate-toheavy intensity physical activity)was registered in 41%of PA and only 9%of CBT group(P<0.007).The6-min walk test increased by 139±26 m in PA and by only 43±38 m in CBT(P<0.001)and VO2max by8.2±3.8 mL/kg per minute and 3.3±2.7 mL/kg per minute,respectively(P<0.002).After adjustment for propensity,weight loss>7%was significantly associated with CBT group at one year(OR=6.21;95%CI:1.23-31.30),whereas PA-R>3 was associated with PA group(10.31;2.02-52.63).Liver enzymes decreased to values within normal limits in 36%of PA cases and61%of CBT(P<0.070).Estimated liver fat(Kotronen index)fell below the fatty liver threshold in 36%of PA and 34%and CBT cases at one-year(not different).Also the fatty liver index and the visceral adiposity index improved to a similar extent.CONCLUSION:Intensive psychological counseling for PA produces hepatic effects not different from standard CBT,improving physical fitness and liver fat independent of weight loss.Strategies promoting exercise are worth and effective in motivated patients,particularly in lean NAFLD patients where large weight loss cannot be systematically pursued. | Luca Montesi Chiara Caselli Elena Centis Chiara Nuccitelli Simona Moscatiello Alessandro Suppini Giulio Marchesini | 2014 | World Journal of Gastroenterology2014，20，29： | 3 |
| 8 | Body composition changes after transjugular intrahepatic portosystemic shunt in patients with cirrhosis显示文摘AIM:To investigate the effect of transjugular intra-hepatic porto-systemic shunt (TIPS) on malnutrition in portal hypertensive cirrhotic patients.METHODS: Twenty-one patients with liver cirrhosis and clinical indications for TIPS insertion were investigated before and 1, 4, 12, 52 wk after TIPS. For each patient we assayed body composition parameters [dry lean mass, fat mass, total body water (TBW)], routine liver and kidney function tests, and free fatty acids (FFA). Glucose and insulin were measured for the calculation of the homeostasis model assessment insulin resistance (HOMA-IR); liver function was measured by the galactose elimination capacity (GEC); the severity of liver disease was graded by model for end-stage liver disease (MELD).RESULTS: Porto-systemic gradient decreased after TIPS (6.0±2.1 mmHg vs 15.8±4.8 mmHg, P<0.001). Patients were divided in two groups according to initial body mass index. After TIPS, normal weight patients had an increase in dry lean mass (from 10.9±5.9 kg to 12.7±5.6 kg, P=0.031) and TBW (from 34.5±7.6 L to 40.2±10.8 L,P=0.007), as well as insulin (from 88.9±49.2 pmol/L to 164.7±107.0 pmol/L,P=0.009) and HOMA-IR (from 3.36%±2.18% to 6.18%±4.82%,P=0.023). In overweight patients only FFA increased significantly (from 0.59±0.24 mmol/L to 0.93±0.34 mmol/L, P=0.023).CONCLUSION: TIPS procedure is effective in lowering portal pressure in patients with portal hypertension and improves body composition without significant changes in metabolic parameters. | Jonathan Montomoli Peter Holland-Fischer Giampaolo Bianchi Henning GrФnbk Hendrik Vilstrup Giulio Marchesini Marco Zoli | 2010 | World Journal of Gastroenterology2010，16，3： | 3 |
| 9 | Bedrock geology interacts with altitude in affecting leaf growth and foliar nutrient status of mountain vascular plants显示文摘Aims Altitude is often used as a proxy for ascertaining how warming affects plant growth and leaf level properties.However,we have a poor understanding of how the effects of altitude-related warming varies across geology.therefore,this study examined the independ-ent and interactive effects of altitude and geology and species on plant growth and foliar nutrient status.Methods We determined leaf growth rates and concentrations of major nutrients(nitrogen,N and phosphorus,P)in leaves of five spe-cies across two altitudinal gradients(1200-2200 m)in the Dolomites(south-eastern Alps,Italy).the two transects were located on carbonate bedrock and silicate bedrock,respec-tively.We also determined concentrations of inorganic and organic N and P forms in soils,andδ15N signature in leaves and soils.Important Findings Foliar N concentrations were unrelated to bedrock geology.the negative foliarδ^(15)N signature suggested that organic N was the primary source of N supply across the gradients.Foliar P concentrations were strongly affected by bedrock geology and their altitudinal patterns depended on the concentrations of organic and inorganic P forms in the soil.Phosphates and organic P appeared to be the main sources of P supply.Leaf growth rates increased with higher altitude on silicate bedrock and decreased with higher altitude on carbonate bedrock and presented a significant positive correlation with foliar N:P.In conclusion,bedrock geology inter-acted with altitude in controlling the foliar nutrient status mainly owing to availability of soil P and its effect on foliar nutrient stoichiometry. | Renato Gerdol Roberta Marchesini Paola Iacumin | 2017 | Journal of Plant Ecology2017，10，5： | 2 |
| 10 | The Role of Lifestyle Change in the Prevention and Treatment of NAFLD显示文摘 | Elena Centis Rebecca Marzocchi Alessandro Suppini Riccardo Dalle Grave Nicola Villanova Ingrid J Hickman Giulio Marchesini | 2013 | Current Pharmaceutical Design2013，，29： | 2 |
| 11 | 超声弹性成像在不可触及的乳腺病灶中的作用显示文摘该研究的目的是评估超声弹性成像鉴别不可触及的乳腺病灶良恶性的诊断效用。278例女性,共293个BI-RADS(乳腺影像报告和数据系统),3~5级不可触及的乳腺病灶,在进行超声引导活检之前先用B超而后使用弹性成像进行评估。在293个病灶中(体积大至2cm)110个(37.5%)组织学表现是恶性的,183个(62.5%)是良性的。 | G. Scaperrotta C. Ferranti C. Costa L. Mariani M. Marchesini L. Suman 何健 | 2009 | 国际医学放射学杂志2009，32，1： | 2 |
| 12 | Association of nonalcoholic fatty liver disease with insulin resistance显示文摘 | Giulio Marchesini Mara Brizi Antonio M Morselli-Labate Giampaolo Bianchi Elisabetta Bugianesi Arthur J McCullough Gabriele Forlani Nazario Melchionda | 1999 | The American Journal of Medicine1999，，5： | 2 |
| 13 | Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome显示文摘 | Giulio Marchesini Elisabetta Bugianesi Gabriele Forlani Fernanda Cerrelli Marco Lenzi Rita Manini Stefania Natale Ester Vanni Nicola Villanova Nazario Melchionda Mario Rizzetto | 2003 | Hepatology2003，，4： | 2 |
| 14 | Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease显示文摘 | P. Loria L.E. Adinolfi S. Bellentani E. Bugianesi A. Grieco S. Fargion A. Gasbarrini C. Loguercio A. Lonardo G. Marchesini F. Marra M. Persico D. Prati G. Svegliati- Baroni | 2010 | Digestive and Liver Disease2010，，4： | 2 |
| 15 | Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon?显示文摘 | G. Targher F. Marra G. Marchesini | 2008 | Diabetologia2008，，11： | 2 |
| 16 | Metformin in non-alcoholic steatohepatitis显示文摘 | Giulio Marchesini Giampaolo Bianchi Sara Tomassetti Marco Zoli Nazario Melchionda | 2001 | The Lancet2001，，9285： | 2 |
| 17 | Clinical features and natural history of nonalcoholic steatosis syndromes显示文摘 | Falck-Ytter Y Younossi ZM Marchesini G | 2001 | Semin Liver Diseases2001，21，1： | 1 |
| 18 | Nonalcoholic fatty liver disease and the metabolic syndrome显示文摘 | Marchesini G Marzocchi R Agostini F | 2005 | Curr Opin Lipidol2005，16，4： | 1 |
| 19 | Minimal effective concentration values of propafenone and 5-hydroxy-propafenone in acute and chronic therapy显示文摘 | Capucci A Boriani G Marchesini B | 1990 | Cardiovascular Drugs and Therapy1990，4，1： | 1 |
| 20 | Obesity- associated liver disease显示文摘 | Marchesini G Moscatiello S Di Domizio S | 2008 | J Clin Endoerinol Metab2008，93，111： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员